We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Thermo Fisher (TMO) Beats on Q3 Earnings & Sales Estimates
Read MoreHide Full Article
Involved in Scientific Research? Then you must have heard about MA-based Thermo Fisher Scientific Inc. (TMO - Free Report) one of the leading scientific instrument manufacturers across the world. Interestingly for this acquisition-friendly company, the latest buy out of Life Technologies is expected to give birth to an unrivaled market leader serving research, Specialty Diagnostics and applied markets.
Currently, Thermo Fisher has a Zacks Rank #2 (Buy) but that could change following its promising third-quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: The current Zacks Consensus Estimate is pegged at $2.24 per share. Thermo Fisher’s adjusted earnings per share of $2.31 is up 13.8% year-over-year in the reported quarter.
Revenues: Thermo Fisher posted third quarter revenues of $5.11 billion, which has also surpassed the Zacks Consensus Estimate for revenues of $5.03 billion.
Thermo Fisher Scientific Inc Price and EPS Surprise
Key Stats: Among its four business segments in the reported quarter, Thermo Fisher delivered revenues of $1.38 billion (up 5%) in Life Sciences Solutions, $1.19 billion (up 32%) in Analytical Instruments, $844 million (up 6%) in Specialty Diagnostics and $1.93 billion (up 15%) in Laboratory Products and Services respectively.
Major Factors: Management seemed upbeat about its impressive third quarter results. Expansion in analytical instrument platforms for both life sciences and applied markets and contribution in gene therapy are key highlights of the quarter. The company has also raised its 2017 revenue and earnings guidance on the back of the acquisition of Patheon, strong operational performance and a more favorable foreign exchange environment.
Check back later for our full write up on this Thermo Fisher earnings report later!
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Image: Bigstock
Thermo Fisher (TMO) Beats on Q3 Earnings & Sales Estimates
Involved in Scientific Research? Then you must have heard about MA-based Thermo Fisher Scientific Inc. (TMO - Free Report) one of the leading scientific instrument manufacturers across the world. Interestingly for this acquisition-friendly company, the latest buy out of Life Technologies is expected to give birth to an unrivaled market leader serving research, Specialty Diagnostics and applied markets.
Currently, Thermo Fisher has a Zacks Rank #2 (Buy) but that could change following its promising third-quarter 2017 earnings report which has just released. (You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here). We have highlighted some of the key details from the just-released announcement below:
Earnings: The current Zacks Consensus Estimate is pegged at $2.24 per share. Thermo Fisher’s adjusted earnings per share of $2.31 is up 13.8% year-over-year in the reported quarter.
Revenues: Thermo Fisher posted third quarter revenues of $5.11 billion, which has also surpassed the Zacks Consensus Estimate for revenues of $5.03 billion.
Thermo Fisher Scientific Inc Price and EPS Surprise
Thermo Fisher Scientific Inc Price and EPS Surprise | Thermo Fisher Scientific Inc Quote
Key Stats: Among its four business segments in the reported quarter, Thermo Fisher delivered revenues of $1.38 billion (up 5%) in Life Sciences Solutions, $1.19 billion (up 32%) in Analytical Instruments, $844 million (up 6%) in Specialty Diagnostics and $1.93 billion (up 15%) in Laboratory Products and Services respectively.
Major Factors: Management seemed upbeat about its impressive third quarter results. Expansion in analytical instrument platforms for both life sciences and applied markets and contribution in gene therapy are key highlights of the quarter. The company has also raised its 2017 revenue and earnings guidance on the back of the acquisition of Patheon, strong operational performance and a more favorable foreign exchange environment.
Check back later for our full write up on this Thermo Fisher earnings report later!
Zacks' Hidden Trades
While we share many recommendations and ideas with the public, certain moves are hidden from everyone but selected members of our portfolio services. Would you like to peek behind the curtain today and view them?
Starting now, for the next month, I invite you to follow all Zacks' private buys and sells in real time from value to momentum...from stocks under $10 to ETF to option movers...from insider trades to companies that are about to report positive earnings surprises (we've called them with 80%+ accuracy). You can even look inside portfolios so exclusive that they are normally closed to new investors.
Click here for Zacks' secret trade>>